MXPA04001114A - Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them. - Google Patents

Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.

Info

Publication number
MXPA04001114A
MXPA04001114A MXPA04001114A MXPA04001114A MXPA04001114A MX PA04001114 A MXPA04001114 A MX PA04001114A MX PA04001114 A MXPA04001114 A MX PA04001114A MX PA04001114 A MXPA04001114 A MX PA04001114A MX PA04001114 A MXPA04001114 A MX PA04001114A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
preparation
compositions containing
kinase inhibitors
aminoindazole derivatives
Prior art date
Application number
MXPA04001114A
Other languages
Spanish (es)
Inventor
Amici Raffaella
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of MXPA04001114A publication Critical patent/MXPA04001114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
MXPA04001114A 2001-09-26 2002-09-19 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them. MXPA04001114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96216201A 2001-09-26 2001-09-26
PCT/EP2002/010534 WO2003028720A1 (en) 2001-09-26 2002-09-19 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MXPA04001114A true MXPA04001114A (en) 2004-05-20

Family

ID=25505498

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001114A MXPA04001114A (en) 2001-09-26 2002-09-19 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.

Country Status (19)

Country Link
US (1) US7511136B2 (en)
EP (2) EP1820503B1 (en)
JP (1) JP4542338B2 (en)
KR (1) KR20040047869A (en)
CN (1) CN1556702A (en)
AT (1) ATE495741T1 (en)
BR (1) BR0212841A (en)
CA (1) CA2460145C (en)
CZ (1) CZ2004359A3 (en)
DE (1) DE60238999D1 (en)
EA (1) EA007430B1 (en)
ES (2) ES2380054T3 (en)
IL (1) IL160744A0 (en)
MX (1) MXPA04001114A (en)
NO (1) NO20041086L (en)
NZ (1) NZ531765A (en)
PL (1) PL368347A1 (en)
WO (1) WO2003028720A1 (en)
ZA (1) ZA200401848B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572200B1 (en) 2002-12-12 2011-08-17 Aventis Pharma S.A. Aminoindazole derivatives and use thereof as kinase inhibitors
FR2848554A1 (en) * 2002-12-12 2004-06-18 Aventis Pharma Sa New aminoindazole derivatives are kinase inhibitors, useful in the treatment of neurodegenerative diseases, obesity, metabolic disorders, diabetes, hypertension, polycystic ovarian syndrome, cancers and other disorders
UA81790C2 (en) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Substituted derivatives of pyrolopyrazol as kinaze inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
GEP20094664B (en) 2003-05-22 2009-04-10 Nerviano Medical Sciences Srl Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050107386A1 (en) * 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
US7994196B2 (en) 2004-02-12 2011-08-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
EP1747202A1 (en) * 2004-02-27 2007-01-31 F.Hoffmann-La Roche Ag Indazole derivatives and pharmaceutical compositions containing them
EP1647549A1 (en) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
EP1904503B1 (en) 2005-07-19 2013-11-06 Nerviano Medical Sciences S.R.L. 1h-thieno[2,3-c]-pyrazole compounds useful as kinase inhibitors
MX2008002385A (en) 2005-08-25 2008-03-18 Hoffmann La Roche P38 map kinase inhibitors and methods for using the same.
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
JP5131990B2 (en) * 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド Kinase inhibitors and methods of use thereof
ES2442491T3 (en) 2006-03-03 2014-02-11 Nerviano Medical Sciences S.R.L. Active bicyclopyrazoles as kinase inhibitors
JPWO2008001886A1 (en) * 2006-06-30 2009-11-26 協和発酵キリン株式会社 Aurora inhibitor
DE102006030479A1 (en) * 2006-07-01 2008-03-20 Merck Patent Gmbh indazole
BRPI0719883A2 (en) 2006-10-09 2015-05-05 Takeda Pharmaceutical Kinase Inhibitors
WO2008070994A1 (en) 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
JP2010513370A (en) 2006-12-19 2010-04-30 エフ．ホフマン−ラ ロシュ アーゲー Pyrazolo [3,4-d] pyrimidine p38 MAP kinase inhibitor
MX2009006401A (en) * 2006-12-20 2009-06-23 Nerviano Medical Sciences Srl Indazole derivatives as kinase inhibitors for the treatment of cancer.
ES2546816T3 (en) 2007-02-27 2015-09-28 Nerviano Medical Sciences S.R.L. Active isoquinolinpyrrolopyridinones as kinase inhibitors
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
WO2008156757A1 (en) * 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
CN106008460B (en) * 2008-01-08 2022-08-12 默沙东公司 Pharmaceutically acceptable salts of 2- {4- [ (3S) -piperidin-3-yl ] phenyl } -2H-indazole-7-carboxamide
CN102105148B (en) 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 Therapeutic combination comprising an AURORA kinase inhibitor and antiproliferative agents
JP5580332B2 (en) * 2008-12-18 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Substituted indazole derivatives active as kinase inhibitors
EP2614065B1 (en) 2010-12-17 2017-04-19 Nerviano Medical Sciences S.r.l. Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
MX342509B (en) * 2011-05-12 2016-10-03 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors.
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
DE102015012050A1 (en) * 2015-09-15 2017-03-16 Merck Patent Gmbh Compounds as ASIC inhibitors and their uses
TW202014408A (en) 2018-07-03 2020-04-16 美商Ｉｆｍ Ｄｕｅ有限公司 Compounds and compositions for treating conditions associated with sting activity
US20230002320A1 (en) * 2019-10-03 2023-01-05 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
TW202317087A (en) * 2021-08-10 2023-05-01 美商Ｉｆｍ Ｄｕｅ有限公司 Compounds and compositions for treating conditions associated with sting activity
WO2023137041A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2023137034A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2023186773A1 (en) 2022-03-30 2023-10-05 Nerviano Medical Sciences S.R.L. Substituted 3-amino indazole derivatives as kinase inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474964A (en) * 1892-05-17 Electrically-heated matrix-press
US28939A (en) 1860-06-26 Improvement in stills
US2478048A (en) * 1943-01-23 1949-08-02 Winthrop Stearns Inc Sulfanilamidoindazoles and method of production
BE626284A (en) 1962-04-28
US3755332A (en) 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
DE2458965C3 (en) 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazole-N-carboxylic acid derivatives, process for their preparation and pharmaceuticals containing them
JPS51143010A (en) * 1975-06-04 1976-12-09 Kao Corp Stable bleaching detergent composition
DE2653005A1 (en) * 1975-12-03 1977-06-08 Sandoz Ag NEW ORGANIC COMPOUNDS, THEIR USE AND PRODUCTION
JPS5754175A (en) * 1980-09-19 1982-03-31 Asahi Chem Ind Co Ltd Novel 3-aminoindazole derivative
DE3166987D1 (en) * 1980-09-18 1984-12-06 Asahi Chemical Ind 3-aminoindazole derivatives and process for preparation thereof
EP0090972B1 (en) * 1982-03-17 1990-05-30 Asahi Kasei Kogyo Kabushiki Kaisha Indazole derivatives
JPS6061569A (en) 1983-09-16 1985-04-09 Asahi Chem Ind Co Ltd Novel amine derivative substitued in the 3-position
JPS60172969A (en) * 1984-02-16 1985-09-06 Asahi Chem Ind Co Ltd Production of indazole derivative
JP2567621B2 (en) 1986-08-22 1996-12-25 塩野義製薬株式会社 Method for ortho-cyanation of phenols or phenylamines
US4864032A (en) 1987-07-02 1989-09-05 Ortho Pharmaceutical Corporation Process for the preparation of indazoles
FR2661669B1 (en) 1990-05-04 1992-08-14 Francais Ciments ADDITIVE FOR CONCRETE PRODUCTS.
JP3148960B2 (en) * 1993-04-12 2001-03-26 コニカ株式会社 Photo cyan coupler
JP3245765B2 (en) * 1994-07-05 2002-01-15 コニカ株式会社 Photo cyan coupler
AU699367B2 (en) * 1995-06-02 1998-12-03 Sanofi-Aventis Isoindole derivatives, their preparation and their application in therapy
DE19534649A1 (en) 1995-09-19 1997-03-20 Hoechst Ag 2-cyano-3-mercaptocrotonic acid amides
WO1999032111A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
WO1999055335A1 (en) * 1998-04-30 1999-11-04 Basf Aktiengesellschaft Substituted tricyclic pyrazole derivatives with protein kinase activity
YU54202A (en) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Indazole compounds,pharmaceutical compositions,and methods for mediating or inhibiting cell proliferation
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US7135288B2 (en) * 2002-09-27 2006-11-14 Ut-Battelle, Llc Combinatorial synthesis of ceramic materials

Also Published As

Publication number Publication date
EP1820503A2 (en) 2007-08-22
NZ531765A (en) 2006-02-24
ES2380054T3 (en) 2012-05-08
EP1820503A3 (en) 2008-05-21
EA200400476A1 (en) 2004-08-26
PL368347A1 (en) 2005-03-21
CZ2004359A3 (en) 2004-09-15
CA2460145A1 (en) 2003-04-10
CA2460145C (en) 2011-04-26
BR0212841A (en) 2004-08-03
KR20040047869A (en) 2004-06-05
DE60238999D1 (en) 2011-03-03
ZA200401848B (en) 2005-03-07
ATE495741T1 (en) 2011-02-15
EA007430B1 (en) 2006-10-27
ES2357502T3 (en) 2011-04-27
CN1556702A (en) 2004-12-22
WO2003028720A1 (en) 2003-04-10
US7511136B2 (en) 2009-03-31
NO20041086L (en) 2004-03-15
JP2005512967A (en) 2005-05-12
JP4542338B2 (en) 2010-09-15
US20040254177A1 (en) 2004-12-16
EP1432416B1 (en) 2011-01-19
EP1820503B1 (en) 2012-02-22
EP1432416A1 (en) 2004-06-30
IL160744A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
MXPA04001114A (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.
MXPA04000920A (en) Aminoisoxazole derivatives active as kinase inhibitors.
MXPA02012164A (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
CA2486101A1 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
MXPA05009719A (en) Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
GB0330043D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
MXPA06000302A (en) Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
RS20060004A (en) Pyrrolo/3,4-c/pyrazole derivatives active as kinase inhibitors
DE602004014163D1 (en) PYRIMIDYLPYRROL DERIVATIVES ACTING AS KINASEINHIBITORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal